IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9777019 B1

PDFFull Text
Date of Patent:
Oct. 03, 2017

Filed:

Feb. 11, 2016

Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use

Applicant:

Amgen Inc., Thousand Oaks, CA (US);

Inventors:

Ryan White, Somerville, MA (US);

Yuan Cheng, Newbury Park, CA (US);

Ana Elena Minatti, Santa Monica, CA (US);

Bryant Yang, Agoura Hills, CA (US);

Xiao Mei Zheng, Natick, MA (US);

Patricia Lopez, Woodland Hills, CA (US);

Jason B. Human, Boston, MA (US);

Oleg Epstein, Belmont, MA (US);

Ted Judd, Granada Hills, CA (US);

Kelvin Sham, Thousand Oaks, CA (US);

Qiufen Xue, Thousand Oaks, CA (US);

Assignee:

Amgen Inc., Thousand Oaks, CA (US);

Attorney:

Markus Bergauer

Primary Examiner:

Brian McDowell

Int. Cl.
CPC ...
A61K 31/537 (2006.01); A61K 31/547 (2006.01); C07D 498/10 (2006.01); C07D 513/10 (2006.01); C07D 498/20 (2006.01); C07D 513/20 (2006.01);
U.S. Cl.
CPC ...
C07D 498/10 (2013.01); C07D 498/20 (2013.01); C07D 513/10 (2013.01); C07D 513/20 (2013.01);
Abstract

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, A, A, A, A, A, A, L, R, R, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Find Patent Forward Citations

Loading…